Medical studies over the past 40 years have shown that many forms of kidney disease are progressive, potentially leading to end-stage kidney disease and renal failure. These studies have also shown that early detection of chronic kidney disease (CKD) and use of medical and lifestyle interventions may slow the progression of CKD and reduce associated healthcare costs, which approach $34B annually (about 15% of the Medicare budget).
DialySensors, Inc. has recently invented and extensively validated Raman Chemometric Urinalysis (Rametrix™) to analyze urine and to screen for the presence and stage of CKD. The Rametrix™ screen has >95% sensitivity and >95% specificity for detecting late-stage CKD.
Rametrix™ technology uses off-the-shelf, low-profile Raman spectrometers, our proprietary computational tools, and our extensive patient database. No sample preparation of urine specimens is required, only a single collection is needed, results are available in about 5 minutes, and the analysis can be performed for less than $1 per specimen.
The slide show below provides a description of how Rametrix™ works in CKD screening. Our 2-page White Paper with expanded information is also available for download below. Please contact us with further inquiries.
The following is our full 2-page White Paper describing the Rametrix™ urine screen for CKD